53 results about "Brain edema" patented technology

Embodiments of the present invention relate to a system and method of detecting or monitoring brain edema in a patient. One embodiment of the present invention includes emitting a first light into the patient's brain tissue at a first wavelength, emitting a second light into the patient's brain tissue at a second wavelength, detecting the first and second lights after dispersion by the brain tissue at a detector, and determining an amount of water proximate the brain tissue based on the detected first and second lights.

The invention relates to the field of medical technology, which discloses a new usage of a petasites tricholobus franch extract and the contained bakkenolide compound in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases. The biological activity tests show that, the petasites tricholobus franch extract and the contained bakkenolide compound can significantly reduce the encephalic necrosis percentage of the rats with local cerebral ischemia, improve the behavior score of the ischemic rats and alleviate volume of brain edema and cerebral infarction of the rats with ischemia reperfusion injury, thus prompting that the petasites tricholobus franch extract and the contained bakkenolide compound have significant protective effect on the cerebral ischemia injury. The petasites tricholobus franch extract and the contained bakkenolide compound can further significantly reduce the J-point displacement caused by ISO and the LDH level in plasma, significantly reduce the scope of myocardial ischemic myocardial infarction of the rats caused by coronary artery ligation and lower the LDH level in the plasma of the rats with the myocardial ischemia. As the petasites tricholobus franch extract and the contained bakkenolide compound have good effects on the prevention and the treatment for heart and brain ischemic diseases aspects, the petasites tricholobus franch extract and the contained bakkenolide compound can be used in the preparation of drugs for prevention and treatment for cardiovascular and cerebrovascular diseases, including coronary heart disease, cerebral ischemia, cerebral infarction (stroke), myocardial infarction and so on.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and / or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Disclosed is a method of treating or preventing a disease or disorder of the central nervous system (CNS) in a patient comprising administering transcranially, for example, directly to the skull, an effective amount of an anti-inflammatory agent to the patient. Examples of the anti-inflammatory agent include glutathione and inhibitors of purinergic receptors such as P2X4, P2X7, P2Y6, and P2Y12 receptors. Examples of disease or disorder of the CNS include brain injury, particularly traumatic brain injury, inflammation, infection, degeneration of brain cells, stroke, brain edema, tumor, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Also disclosed is a kit comprising at least one anti-inflammatory agent and printed materials containing instructions for transcranially administering the anti-inflammatory agent to the patient having a disease or disorder of the CNS.

The invention discloses injection of mannite and glycerol, which contains mannite, glycerol and water for injection. Furthermore, the invention also discloses a method for preparing the injection, which comprises the following steps: taking the mannite and the glycerol, dissolving into the water for injection, filtering and filling. The injection of the mannite and the glycerol is clinically usedfor treating cerebrovascular diseases, brain trauma, cerebral tumors, intracranial inflammation and the diseases of acute and chronic intracranial hypertension, hydrocephalus and the like caused by other reasons. The injection of the mannite and the glycerol has the functions of lowering the intracranial pressure quickly and eliminating the hydrocephalus and can also avoid death because of acute renal failure caused by the injury of the kidney; the injection of the mannite and the glycerol suppresses the apoptosis of neural cells and achieves the function of protecting the brain; the functionof lowering the intracranial pressure is stable and has long retention time; crystals occurring because of the change of the air temperature or in the processes of storage and transportation are eliminated; and the glycerol is used as a caloric agent and can improve and recover the energy metabolism of the important viscera of the heart, the brain, the kidney and the like during oxygen deficiency. The injection of the mannite and the glycerol is a very effective, stable and safe medicine for promoting urination and removing water clinically.

The invention relates to the technical field of medicine, and the invention provides the use of smilaxamide for preparing a medicine for preventing and treating ischemic stroke. According to the pharmacological test of the focal cerebral ischemia model in mice, the present invention finds that smilaxamide can significantly improve the behavioral symptoms caused by cerebral ischemia-reperfusion injury in mice, reduce the volume of cerebral infarction, and reduce cerebral edema in mice with cerebral ischemia degree. Therefore, smilaxamide can be used to prepare medicines for preventing and treating ischemic stroke.